This newer mode of administration for immunotherapy comes with benefits and risks. It is important for a person to work with a doctor when making treatment decisions for upper gastrointestinal (GI) ...
SurvivorNet on MSN
A simpler delivery system: FDA approves subcutaneous injection version of powerful targeted drug isatuximab for multiple myeloma
A new under‑the‑skin version of isatuximab is now approved, giving multiple myeloma patients a much faster and more ...
Y our oncologist may prescribe immunotherapy at various points in the cancer treatment journey. Immunotherapy is known to be especially effective in treating late-stage cancer that hasn’t responded to ...
Stelara (ustekinumab) is a brand-name prescription drug approved to treat Crohn’s disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. You should always administer Stelara according ...
Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for patients with solid tumors. On Dec. 27, 2024, the Food and Drug ...
Trial Supports Subcutaneous Isatuximab as Effective Alternative to IV Version: Xavier Leleu, MD, PhD
The phase 3 IRAKLIA trial found that subcutaneous isatuximab delivered via an on-body system was as effective and safe as intravenous (IV) administration in relapsed/refractory multiple myeloma, ...
Keytruda Qlex, a subcutaneous formulation, is FDA-approved for solid tumors in patients 12 and older, offering an alternative to intravenous administration. Study MK-3475A-D77 showed comparable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results